Diane L Reidy-Lagunes

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors
    Diane L Reidy
    Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10065, USA
    Nat Clin Pract Oncol 6:143-52. 2009
  2. ncbi request reprint Systemic therapy for advanced pancreatic neuroendocrine tumors: an update
    Diane L Reidy-Lagunes
    Division of Solid Tumor Oncology, Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill College of Medicine, Cornell University, New York, NY, USA
    J Natl Compr Canc Netw 10:777-83. 2012
  3. doi request reprint Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different?
    Diane Reidy-Lagunes
    Division of Solid Tumor Oncology, Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Curr Oncol Rep 14:249-56. 2012
  4. pmc Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer
    Diane Lauren Reidy
    Department of Medicine, Division of Solid Tumors, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howard 1004, New York, NY 10065, USA
    J Clin Oncol 28:4240-6. 2010
  5. doi request reprint A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors
    Diane L Reidy-Lagunes
    Department of Medicine, Division of Solid Tumors, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 118:4795-800. 2012
  6. ncbi request reprint Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial
    Deborah Schrag
    All authors Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 32:513-8. 2014
  7. ncbi request reprint Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer
    Andrea Cercek
    From the aGastrointestinal Oncology Service, Department of Medicine, bDepartment of Radiation Therapy, and cColorectal Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
    J Natl Compr Canc Netw 12:513-9. 2014
  8. ncbi request reprint Bevacizumab 5 mg/kg can be infused safely over 10 minutes
    Diane L Reidy
    Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:2691-5. 2007
  9. doi request reprint A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma
    Ghassan K Abou-Alfa
    Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States Department of Internal Medicine, Weill Medical College at Cornell University, New York, NY, United States Electronic address
    J Hepatol 60:319-24. 2014
  10. doi request reprint Resolution of hepatic encephalopathy following hepatic artery embolization in a patient with well-differentiated neuroendocrine tumor metastatic to the liver
    Joseph P Erinjeri
    Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cardiovasc Intervent Radiol 33:610-4. 2010

Detail Information

Publications10

  1. ncbi request reprint Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors
    Diane L Reidy
    Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10065, USA
    Nat Clin Pract Oncol 6:143-52. 2009
    ..We will discuss the data on therapies currently used to treat well-differentiated NETs, and the strategies being used in clinical trials...
  2. ncbi request reprint Systemic therapy for advanced pancreatic neuroendocrine tumors: an update
    Diane L Reidy-Lagunes
    Division of Solid Tumor Oncology, Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill College of Medicine, Cornell University, New York, NY, USA
    J Natl Compr Canc Netw 10:777-83. 2012
    ..This article discusses these recent trials and provides an update of systemic treatment options in patients with well-differentiated pancNETs...
  3. doi request reprint Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different?
    Diane Reidy-Lagunes
    Division of Solid Tumor Oncology, Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Curr Oncol Rep 14:249-56. 2012
    ..Such a discovery could potentially be used to stratify treatment and such studies are currently being investigated...
  4. pmc Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer
    Diane Lauren Reidy
    Department of Medicine, Division of Solid Tumors, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howard 1004, New York, NY 10065, USA
    J Clin Oncol 28:4240-6. 2010
    ....
  5. doi request reprint A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors
    Diane L Reidy-Lagunes
    Department of Medicine, Division of Solid Tumors, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 118:4795-800. 2012
    ..Therefore, the authors of this report evaluated the safety and efficacy of MK-0646, a fully human monoclonal antibody (MoAb) that binds to the IGF-1R, as monotherapy in patients with metastatic, well-differentiated NETs...
  6. ncbi request reprint Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial
    Deborah Schrag
    All authors Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 32:513-8. 2014
    ..We evaluated preoperative infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX)/bevacizumab with selective rather than consistent use of chemoradiotherapy...
  7. ncbi request reprint Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer
    Andrea Cercek
    From the aGastrointestinal Oncology Service, Department of Medicine, bDepartment of Radiation Therapy, and cColorectal Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
    J Natl Compr Canc Netw 12:513-9. 2014
    ..FOLFOX and chemoradiation before planned TME results in tumor regression, a high rate of delivery of planned therapy, and a substantial rate of pathCRs, and offers a good platform for nonoperative management in select patients. ..
  8. ncbi request reprint Bevacizumab 5 mg/kg can be infused safely over 10 minutes
    Diane L Reidy
    Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:2691-5. 2007
    ..We sought to determine if the initial prolonged infusion was still necessary and if an infusion time of fewer than 30 minutes could be safely used...
  9. doi request reprint A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma
    Ghassan K Abou-Alfa
    Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States Department of Internal Medicine, Weill Medical College at Cornell University, New York, NY, United States Electronic address
    J Hepatol 60:319-24. 2014
    ..IGF-IR is implicated in hepatic carcinogenesis. This and preliminary evidence of biological activity of anti-IGF-1R monoclonal antibody cixutumumab in phase I trials prompted this phase II study...
  10. doi request reprint Resolution of hepatic encephalopathy following hepatic artery embolization in a patient with well-differentiated neuroendocrine tumor metastatic to the liver
    Joseph P Erinjeri
    Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cardiovasc Intervent Radiol 33:610-4. 2010
    ....